AVDL NASDAQ
Avadel Pharmaceuticals plc
1W: +0.1%
1M: +0.6%
3M: +43.7%
1Y: +104.5%
3Y: +208.7%
5Y: +207.4%
$21.64
Last traded 2025-12-31 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$169M
+504.8% ▲
5Y CAGR: +23.4%
Gross Profit
$154M
+467.3% ▲
5Y CAGR: +26.7%
Operating Income
-$42M
+69.2% ▲
Net Income
-$49M
+69.5% ▲
EPS (Diluted)
$-0.51
+74.5% ▲
EBITDA
-$36M
+76.1% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $22M | $0 | $0 | $28M | $169M |
| YoY Growth | -62.3% | -100.0% | +0.0% | +0.0% | +504.8% |
| Cost of Revenue | $6M | $0 | $0 | $846K | $15M |
| Gross Profit | $17M | $0 | $0 | $27M | $154M |
| Gross Margin | 74.3% | — | — | 97.0% | 91.0% |
| R&D Expenses | $20M | $17M | $21M | $13M | $15M |
| SG&A Expenses | $32M | $68M | $75M | $152M | $181M |
| Operating Expenses | $11M | $86M | $99M | $165M | $196M |
| Operating Income | $6M | -$86M | -$99M | -$138M | -$42M |
| Operating Margin | 26.0% | — | — | -493.0% | -25.1% |
| Interest Expense | $13M | $10M | $12M | $10M | $11M |
| Income Before Tax | -$5M | -$93M | -$111M | -$161M | -$49M |
| Tax Expense | -$12M | -$16M | $26M | -$501K | -$247K |
| Net Income | $7M | -$77M | -$137M | -$160M | -$49M |
| Net Margin | 31.5% | — | — | -573.2% | -28.9% |
| EPS (Diluted) | $0.13 | $-1.32 | $-2.29 | $-2.00 | $-0.51 |
| EBITDA | $10M | -$82M | -$98M | -$149M | -$36M |
| Shares Outstanding | 55M | 59M | 60M | 80M | 95M |